Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 VaccineBNT162b2 화이자-바이오엔텍 SARS-CoV-2 백신을 접종한 혈액투석, 복막투석, 신장이식 환자 말기 신장질환 환자의 국소 및 전신 면역 손상Article Published on 2022-07-222022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] analyzed anti-S anti-S IgG antibodies antibody binding antibody unit BNT162b2 cellular component clinical control group COVID-19 COVID-19 in patient COVID-19 vaccine dose effective End-stage renal disease ESRD Guidance HD group healthy individual Hemodialysis high mortality rate highest IFN-γ IgA IgG Immunity Immunoglobulin G Impaired Interferon-gamma investigated kidney transplant recipient Local Messenger RNA MONITOR mRNA participant Patient patients performed Peritoneal dialysis Pfizer Pfizer-BioNTech positive produced recipient required Research Responder SARS-CoV-2 Seroconversion seroconversion rate seronegative patient seropositive subjects systemic tested therapy Transplant transplantation Trial registration Vaccine vaccine response [DOI] 10.3389/fimmu.2022.832924 PMC 바로가기 [Article Type] Article
COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteinsCOVID-19 백신 접종은 고유의 코로나바이러스 스파이크 단백질로 보존된 에피토프에 대한 진화하는 교차 반응성 항체 반응을 이끌어냅니다Article Published on 2022-07-052022-09-11 Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, 치료기술, [키워드] Alanine antibody conserved coronavirus coronavirus spike protein CoV COVID-19 pandemic COVID-19 vaccination CoVs CP: Immunology CP: Microbiology cross-reactive cross-reactive antibody detectable elicit Endemic epitope Epitopes experiments homolog identify Immunity immunology longitudinal samples mechanism Microbiology mRNA mRNA-1273 mRNA-1273 vaccine multiplexed serology observé other coronavirus other coronaviruses phylogenetically reactivity regions residue SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes serology spike subject the vaccine trajectory triggered vaccination vaccine response vaccine-induced antibody response widespread [DOI] 10.1016/j.celrep.2022.111022 PMC 바로가기 [Article Type] Article
Frailty and COVID-19 mRNA Vaccine Antibody Response in the COVID-19 Community Research PartnershipObservational Study Published on 2022-07-052022-10-05 Journal: The Journals of Gerontology Series A: Biological S [Category] 임상, [키워드] 95% CI 95% confidence interval adjusted adjusted odds ratio Adults affected age antibody Antibody detection Antibody Response Antibody testing Care categories COVID-19 COVID-19 mRNA Vaccination COVID-19 mRNA vaccines Follow-up frailty Health Immune function. independent individual individuals interquartile range less logistic regression models median Moderna mRNA mRNA vaccine observational study Older participant partnership Pfizer positive response sensitivity Seroconversion seroconvert seroreversion subsequent vaccination Vaccine vaccine response while [DOI] 10.1093/gerona/glac095 PMC 바로가기 [Article Type] Observational Study
Case of adult-onset Kawasaki disease and multisystem inflammatory syndrome following SARS-CoV-2 vaccinationSARS-CoV-2 예방접종 후 성인 발병 가와사키병 및 다기관 염증 증후군 증례Case Reports Published on 2022-07-042022-09-11 Journal: BMJ case reports [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] absence Adult patients Adverse reactions antibodies antibody children condition COVID-19 criteria demonstrated desquamation dose Effect hands Immunoglobulin immunological products and vaccines infection with SARS-CoV-2 Inflammatory Intervention Intravenous immunoglobulin Kawasaki disease limit MIS occur Patient postvaccination recent reverse transcriptase reverse transcriptase PCR rheumatology SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleocapsid SARS-CoV-2 RNA SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine Spike protein syndrome tested Treatment Unwanted effects / adverse reactions vaccination Vaccination/immunisation vaccine response widespread [DOI] 10.1136/bcr-2022-249094 PMC 바로가기 [Article Type] Case Reports
A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys혈청학적 조사를 위한 BBV152(Covaxin) 전체 비리온 비활성화 SARS-CoV-2 백신의 수혜자의 감염 상태를 결정하기 위한 기계 학습 기반 접근 방식Article Published on 2022-07-012022-09-11 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 치료법, [키워드] age antibody antigens applied approach assessment assessments BBV152 Breakthrough infection can be used Clustering Consensus Covaxin COVID-19 COVID-19 pandemic Data science dataset Delta determine dose doses effective Effectiveness Ensemble methods generate help immune response inactivated Infection machine machine learning ML model neutralization Neutralization assay neutralize nucleocapsid antigens Population predicted premise Protein random recipient recipients SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine sequence sequences serological survey Sex spike Spike protein statistical subject subjects subset Support the vaccine type strain uninfected Vaccine vaccine response viral evolution Viral proteins virion wild type wild-type strain [DOI] 10.1016/j.compbiomed.2022.105419 PMC 바로가기 [Article Type] Article
OMICRON: Virology, immunopathogenesis, and laboratory diagnosisOMICRON: 바이러스학, 면역병리학 및 실험실 진단Review Published on 2022-07-012022-09-11 Journal: The journal of gene medicine [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addressed Alpha antibody approach B.1.1.529 Beta Biology Booster vaccine Clinical sign coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 decrease Delta Diagnosis diagnostic dose Gamma Genetic Genome Health Organization Immunopathogenesis immunopathological increased risk Infection Laboratory management Mortality Mutation omicron Omicron variant pediatrics Re-infection receptor binding site respiratory virus risk severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severity Signs and symptoms Spike protein Spread Symptoms therapeutic Transmissibility understanding Vaccine vaccine response Vaccines variant variants variants of concern Virology World Health Organization [DOI] 10.1002/jgm.3435 PMC 바로가기 [Article Type] Review
Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccineBNT162b2 백신 투여 10개월 후 대규모 의료 전문가 집단에서 항체 역가 동역학 및 SARS-CoV-2 감염 평가Multicenter Study Published on 2022-07-012022-09-11 Journal: Journal of Immunological Methods [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, [키워드] administration Anti-spike antibody Antibody Response Antibody titer BNT162b2 BNT162b2 vaccine booster dose Coverage COVID-19 COVID-19 vaccine decrease detectable difference dose Efficacy first dose follow-up period hcp Healthcare professional humoral Humoral response immune response Infection large cohort median titer mRNA vaccine multicenter multicenter study occurred population studies Post-vaccination infection Prevalence receiving Receptor-binding domain Roche Roche anti-SARS-CoV-2-S SARS-COV-2 infection SARS-CoV-2 infections serological test seronegative seronegatives seropositive serum serum antibody shown Spike protein Symptomatology the antibody response the median the receptor-binding domain the SARS-CoV-2 the spike protein time interval time intervals vaccination Vaccination strategy Vaccine vaccine efficacy vaccine response waning immunity was tested were measured within 6 months [DOI] 10.1016/j.jim.2022.113293 PMC 바로가기 [Article Type] Multicenter Study
Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies질병 변형 요법으로 치료받는 다발성 경화증 환자에서 일반적인 3회 투여 일정에 따른 SARS-CoV-2 백신 접종에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age anti-CD20 anti-CD20 treatment antibody benefit COVID-19 disease Disease modifying treatment dose dosing schedule fumarate humoral immune system immunization Immunocompromised interferon medication mRNA vaccination MS multiple sclerosis Part Patient patients patients treated retrospective SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 virus spike tested the vaccine therapy treated treated patients treatment with anti-CD20 vaccination Vaccine vaccine response [DOI] 10.1016/j.msard.2022.103856 PMC 바로가기 [Article Type] Article
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease염증성 장 질환 환자에서 SARS-CoV-2 mRNA 백신 접종 후 6개월 후 항체 반응Article Published on 2022-07-012022-09-11 Journal: Clinical gastroenterology and hepatology : the off [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-spike antibody anti-spike antibody response antibody kinetics Antibody Response completion coronavirus detectable examined IBD Immunosuppression immunosuppressive medications Inflammatory bowel disease Kinetics medication moderate moderate to severe Month mRNA Patient receive response SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine severe acute respiratory syndrome Coronavirus shown subset the SARS-CoV-2 therapy vaccination Vaccinations vaccine response [DOI] 10.1016/j.cgh.2021.12.045 PMC 바로가기 [Article Type] Article
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic임상 실습의 최근 발전: COVID-19 대유행 중 염증성 장 질환 관리Review Published on 2022-07-012022-09-11 Journal: Gut [Category] COVID19(2023년), SARS, 치료기술, [키워드] acquisition adverse outcome adverse outcomes antibody booster dose bowel Breakthrough infection breakthrough infections Cancer cancers Corticosteroid Corticosteroids COVID-19 COVID-19 in patient COVID-19 pandemic Crohn's disease de novo decrease develop diagnoses disease course dose Evidence Future General population Guidance hospitalisation hospitalisations Humoral response humoral responses IBD immune immune response immunosuppressive therapies immunosuppressive therapy increased risk Inflammatory Inflammatory bowel disease management medication medications Necrosis outcome outcomes pandemic Patient patients potential risk primary dose raised receive recent remained Research risk risk of COVID-19 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines TNF treated Treatment ulcerative ulcerative colitis Vaccine vaccine response Vaccines [DOI] 10.1136/gutjnl-2021-326784 PMC 바로가기 [Article Type] Review